Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

Inclusion Criteria: * Participant aged 18 years or older on the day of inclusion. * Participant able to attend scheduled visits and to comply with the study procedures during the entire duration of the study. * Participant is in reasonably good health as assessed by the investigator. * Participant willing and able to meet protocol requirements. * Participant willing and able to give informed consent. * For a woman, inability to bear a child or negative serum/urine pregnancy test. Exclusion Criteria: * Self-reported allergy to egg proteins, chicken proteins, or one of the constituents of the vaccine, such as thimerosal or formaldehyde. * An acute illness with or without fever (temperature ≥ 99.5 °F oral) in the 72 hours preceding enrollment in the trial. * Clinically significant findings in vital signs (including temperature ≥ 99.5 °F oral) on review of systems. * Self-reported history of severe adverse event to any influenza vaccine. * Laboratory-confirmed influenza infection or vaccination against influenza in the 6 months preceding enrollment in the study. * Any vaccination in the 14 days preceding enrollment in the study or scheduled between Visit 1 and Visit 3. * Vaccination planned in the 4 weeks following Fluzone® vaccination at Visit 1. * Participation in any other interventional drug or vaccine trial within the 30 days preceding or during enrollment into this study. * Immunocompromising or immunosuppressive therapy (including systemic steroid use for 2 weeks or more), cancer chemotherapy, or radiation therapy at the time of enrollment, planned during the period of this study, or at any time within the past 6 months. * Receipt of blood or blood products within the 3 months preceding enrollment in the study. * Diabetes mellitus requiring pharmacological control. * Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine. * Person deprived of freedom by an administrative or court order (having legal or medical guardian). * For women of childbearing potential, a positive urine pregnancy test, breast feeding, or not using a medically approved form of contraception for the duration of the trial. * Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures. * Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination. * Prior personal history of Guillain-Barré syndrome.